12 Month Price Forecast For CTMX
Distance to CTMX Price Forecasts
CTMX Price Momentum
๐ค Considering CytomX (CTMX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 8:49 PM UTC
CTMX Analyst Ratings & Price Targets
Based on our analysis of 15 Wall Street analysts, CTMX has a bullish consensus with a median price target of $3.68 (ranging from $3.25 to $8.00). Currently trading at $0.79, the median forecast implies a 365.8% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Driscoll at Wedbush, projecting a 912.7% upside. Conversely, the most conservative target is provided by Etzer Darout at BMO Capital, suggesting a 311.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTMX Analyst Consensus
CTMX Price Target Range
Latest CTMX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTMX.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 7, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
Nov 11, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
Sep 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
Aug 22, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
Jun 27, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
May 28, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Upgrade | $3.50 |
May 9, 2024 | Wedbush | Robert Driscoll | Outperform | Upgrade | $8.00 |
May 9, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $3.59 |
May 9, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Neutral | Reiterates | $0.00 |
May 6, 2024 | Jefferies | Roger Song | Buy | Upgrade | $8.00 |
May 1, 2024 | BMO Capital | Etzer Darout | Market Perform | Reiterates | $3.25 |
Apr 22, 2024 | JP Morgan | Anupam Rama | Neutral | Upgrade | $0.00 |
Mar 12, 2024 | BMO Capital | Etzer Darout | Market Perform | Maintains | $3.25 |
Mar 12, 2024 | Wedbush | Robert Driscoll | Neutral | Reiterates | $3.00 |
Nov 9, 2023 | Wedbush | Robert Driscoll | Neutral | Maintains | $3.00 |
Nov 8, 2023 | Wedbush | Robert Driscoll | Outperform | Upgrade | $3.00 |
Aug 9, 2023 | BMO Capital | Etzer Darout | Market Perform | Maintains | $3.19 |
Mar 28, 2023 | Mizuho | Mara Goldstein | Neutral | Maintains | $2.00 |
Jan 6, 2023 | BMO Capital | Etzer Darout | Market Perform | Maintains | $3.20 |
Nov 14, 2022 | BMO Capital | Etzer Darout | Market Perform | Downgrade | $2.60 |
Stocks Similar to CytomX Therapeutics Inc
The following stocks are similar to CytomX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CytomX Therapeutics Inc (CTMX) Financial Data
CytomX Therapeutics Inc has a market capitalization of $61.08M with a P/E ratio of 4.9x. The company generates $126.62M in trailing twelve-month revenue with a 10.9% profit margin.
Revenue growth is +26.7% quarter-over-quarter, while maintaining an operating margin of +12.3% and return on equity of +1.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

CytomX Therapeutics Inc (CTMX) Company Overview
About CytomX Therapeutics Inc
Develops innovative biologics for cancer treatment.
The company leverages its proprietary conditional activation platform technology to develop targeted oncology therapeutics. It generates revenue through partnerships and collaborations with major pharmaceutical companies, as well as through the advancement of its product pipeline, which includes bispecific antibodies and antibody-drug conjugates aimed at improving treatment efficacy and safety for cancer patients.
CytomX Therapeutics has a robust development pipeline focusing on various cancer types and has established strategic collaborations with industry leaders such as Amgen and Bristol Myers Squibb. The company is well-positioned in the oncology sector, utilizing its innovative technologies to enhance the therapeutic index of existing treatments while pursuing new therapeutic modalities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
120
CEO
Dr. Sean A. McCarthy DPHIL
Country
United States
IPO Year
2015
Website
www.cytomx.comCytomX Therapeutics Inc (CTMX) Latest News & Analysis
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Providesย Corporate Update
1 month agoCX-2051, a wholly-owned EpCAM PROBODYยฎ ADC program, is progressing well, with initial Phase 1a clinical data in advanced metastatic colorectal cancer expected in H1 2025.
The positive progress on CX-2051 suggests potential for significant breakthroughs in cancer treatment, influencing market sentiment and stock valuations for biotech investors.
CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects.
CytomX Therapeutics' upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and stock price.
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
1 month agoCytomX Therapeutics (CTMX) shows signs of recovery with a hammer chart pattern and revised higher earnings estimates from Wall Street analysts, indicating potential for a near-term turnaround.
CytomX Therapeutics shows potential for recovery with technical support and analyst upgrades, signaling possible future stock price appreciation.
CytomX Therapeutics CEO Sean McCarthy will speak at the Piper Sandler Healthcare Conference on December 4, 2024, at 8:00 a.m. ET.
CytomX Therapeutics' CEO participation in a major healthcare conference can signal potential insights on company performance and strategic direction, influencing investor sentiment and stock price.
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround
2 months agoCytomX Therapeutics (CTMX) is in oversold territory, indicating potential for a trend reversal, supported by analysts raising earnings estimates.
CytomX Therapeutics may see a rebound due to oversold conditions and increased earnings estimates from analysts, signaling potential upward momentum for investors.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) will hold its Q3 2024 earnings conference call on November 7, 2024, at 5:00 PM ET, featuring key executives and analysts from major firms.
The Q3 earnings call will provide insights into CytomX's financial performance and strategic direction, influencing stock valuation and investor sentiment.
Frequently Asked Questions About CTMX Stock
What is CytomX Therapeutics Inc's (CTMX) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, CytomX Therapeutics Inc (CTMX) has a median price target of $3.68. The highest price target is $8.00 and the lowest is $3.25.
Is CTMX stock a good investment in 2025?
According to current analyst ratings, CTMX has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CTMX stock?
Wall Street analysts predict CTMX stock could reach $3.68 in the next 12 months. This represents a 365.8% increase from the current price of $0.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CytomX Therapeutics Inc's business model?
The company leverages its proprietary conditional activation platform technology to develop targeted oncology therapeutics. It generates revenue through partnerships and collaborations with major pharmaceutical companies, as well as through the advancement of its product pipeline, which includes bispecific antibodies and antibody-drug conjugates aimed at improving treatment efficacy and safety for cancer patients.
What is the highest forecasted price for CTMX CytomX Therapeutics Inc?
The highest price target for CTMX is $8.00 from Robert Driscoll at Wedbush, which represents a 912.7% increase from the current price of $0.79.
What is the lowest forecasted price for CTMX CytomX Therapeutics Inc?
The lowest price target for CTMX is $3.25 from Etzer Darout at BMO Capital, which represents a 311.4% increase from the current price of $0.79.
What is the overall CTMX consensus from analysts for CytomX Therapeutics Inc?
The overall analyst consensus for CTMX is bullish. Out of 15 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $3.68.
How accurate are CTMX stock price projections?
Stock price projections, including those for CytomX Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.